

# Sherri R Davies

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5813602/sherri-r-davies-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55 papers	11,670 citations	33 h-index	60 g-index
60 ext. papers	14,148 ext. citations	13.9 avg, IF	4.96 L-index

#	Paper	IF	Citations
55	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.. <i>NAR Cancer</i> , <b>2022</b> , 4, zcac014	5.2	1
54	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. <i>Nature Genetics</i> , <b>2021</b> , 53, 86-99	36.3	44
53	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , <b>2021</b> , 12, 5086	17.4	6
52	Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. <i>Cell Reports</i> , <b>2020</b> , 33, 108276	10.6	33
51	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
50	Research-based PAM50 signature and long-term breast cancer survival. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 179, 197-206	4.4	25
49	Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability. <i>Molecular and Cellular Proteomics</i> , <b>2019</b> , 18, 1630-1650	7.6	5
48	miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 1525-1533	4	5
47	Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. <i>Cell</i> , <b>2019</b> , 177, 1035-1049.e19	56.2	237
46	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , <b>2019</b> , 179, 964-983.e31	58.1	173
45	Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. <i>Cancer Research</i> , <b>2018</b> , 78, 2732-2746	10.1	34
44	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. <i>Cell Reports</i> , <b>2018</b> , 24, 1434-1444.e7	10.6	43
43	Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. <i>Nature Protocols</i> , <b>2018</b> , 13, 1632-1661	18.8	176
42	The prognostic effects of somatic mutations in ER-positive breast cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 3476	17.4	51
41	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. <i>Nature Communications</i> , <b>2017</b> , 8, 14864	17.4	78
40	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. <i>Journal of Molecular Diagnostics</i> , <b>2017</b> , 19, 147-161	5.1	11
39	Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. <i>Science Signaling</i> , <b>2017</b> , 10,	8.8	21

38	Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. <i>Journal of Proteome Research</i> , <b>2017</b> , 16, 4523-4530	5.6	14
37	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. <i>Nature Communications</i> , <b>2016</b> , 7, 12498	17.4	47
36	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. <i>Cell</i> , <b>2016</b> , 166, 755-765	56.2	544
35	An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer. <i>Molecular and Cellular Proteomics</i> , <b>2016</b> , 15, 1060-71	7.6	80
34	Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. <i>Clinical Chemistry</i> , <b>2016</b> , 62, 48-69	5.5	135
33	Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts. <i>Journal of Proteome Research</i> , <b>2016</b> , 15, 691-706	5.6	35
32	QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues. <i>Molecular and Cellular Proteomics</i> , <b>2016</b> , 15, 740-51	7.6	5
31	Integrated Bottom-Up and Top-Down Proteomics of Patient-Derived Breast Tumor Xenografts. <i>Molecular and Cellular Proteomics</i> , <b>2016</b> , 15, 45-56	7.6	53
30	Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1410, 223-36	1.4	25
29	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , <b>2016</b> , 2,	7.8	58
28	Proteogenomics connects somatic mutations to signalling in breast cancer. <i>Nature</i> , <b>2016</b> , 534, 55-62	50.4	938
27	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. <i>BMC Medical Genomics</i> , <b>2015</b> , 8, 54	3.7	242
26	Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. <i>Journal of Proteome Research</i> , <b>2015</b> , 14, 422-33	5.6	24
25	Proteogenomic characterization of human colon and rectal cancer. <i>Nature</i> , <b>2014</b> , 513, 382-7	50.4	900
24	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. <i>Molecular and Cellular Proteomics</i> , <b>2014</b> , 13, 1690-704	7.6	239
23	Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2014</b> , 138, 1507-13	5	2
22	CPTAC Assay Portal: a repository of targeted proteomic assays. <i>Nature Methods</i> , <b>2014</b> , 11, 703-4	21.6	113
21	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. <i>Cell Reports</i> , <b>2013</b> , 4, 1116-30	10.6	447

20	Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2402-12	12.9	117
19	Genome remodelling in a basal-like breast cancer metastasis and xenograft. <i>Nature</i> , <b>2010</b> , 464, 999-1005	50.4	935
18	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5222-32	12.9	546
17	Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 119, 379-90	4.4	107
16	Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 12909-14	11.5	94
15	PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 3955-62	10.1	179
14	Supervised risk predictor of breast cancer based on intrinsic subtypes. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1160-7	2.2	2866
13	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 736-50	9.7	1545
12	A novel tumor necrosis factor alpha-responsive CCAAT/enhancer binding protein site regulates expression of the cartilage-derived retinoic acid-sensitive protein gene in cartilage. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1366-76		9
11	Site-1 protease is essential for endochondral bone formation in mice. <i>Journal of Cell Biology</i> , <b>2007</b> , 179, 687-700	7.3	48
10	Computational identification and functional validation of regulatory motifs in cartilage-expressed genes. <i>Genome Research</i> , <b>2007</b> , 17, 1438-47	9.7	26
9	Site-1 protease is essential for endochondral bone formation in mice. <i>Journal of Experimental Medicine</i> , <b>2007</b> , 204, i28-i28	16.6	
8	A promoter element of the CD-RAP gene is required for repression of gene expression in non-cartilage tissues in vitro and in vivo. <i>Journal of Cellular Biochemistry</i> , <b>2006</b> , 97, 857-68	4.7	13
7	In vivo human Cartilage oligomeric matrix protein (COMP) promoter activity. <i>Matrix Biology</i> , <b>2005</b> , 24, 539-49	11.4	15
6	Alternative splicing of type II procollagen exon 2 is regulated by the combination of a weak 5' splice site and an adjacent intronic stem-loop cis element. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 32700-11	5.4	37
5	Tissue-restricted expression of the Cdrap/Mia gene within a conserved multigenic housekeeping locus. <i>Genomics</i> , <b>2004</b> , 83, 667-78	4.3	7
4	Distribution of the transcription factors Sox9, AP-2, and [delta]EF1 in adult murine articular and meniscal cartilage and growth plate. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2002</b> , 50, 1059-65	3.4	33
3	Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 1896-904		218

2

Doxycycline inhibits type X collagen synthesis in avian hypertrophic chondrocyte cultures. *Journal of Biological Chemistry*, **1996**, 271, 25966-70

5.415

1

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts<sup>2</sup>